Invivyd's REVOLUTION program for VYD2311 advances, but analysts see no shift in long-term revenue growth outlook.
ByAinvest
Friday, Dec 19, 2025 1:30 am ET1min read
IVVD--
Invivyd's latest clinical progress has left its fair value estimate at $10.00 per share, with a slight uptick in the discount rate indicating a modest shift in perceived risk. Analysts interpret the stable long-term revenue growth outlook as reinforcement of expectations for VYD2311's potential to reshape Invivyd's market opportunity. H.C. Wainwright doubled its price target to $10, signaling improved confidence in Invivyd's execution and long-term growth prospects in COVID-19 prevention.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet